Human Serum Paraoxonase Activity Decreases After Vertical Banded Gastroplasty*

• Authors: Bartosz Goyke , Elżbieta Goyke , Tomasz Śledziński , Krystian Adrych , Sylwia Raczyńska , Zbigniew Śledziński , Julian Świerczyński
• Languages of publication: EN

Abstracts

EN

The aim of the study. Investigation of the effect of vertical banded gastroplasty (VBG), which is an effective method of treating patients with morbid obesity on serum paraoxonase (PON) activity.Material and methods. Serum PON activity was measured in twenty eight morbidly obese patients 6 and 12 months after surgery. PON activity was also measured in the serum and liver of rats maintained on a restricted diet for one month.Results. We found that VBG-induced significant reduction in body weight and serum PON activity at 6 and 12 months after surgery. Similar patterns of decreases in serum paraoxonase activity in obese patients after VBG were observed in A, AB and B paraoxonase/esterase phenotypes. After VBG, several clinically relevant events occurred: a) a decrease of serum triacylglycerol concentration was observed; b) no significant changes in total serum cholesterol and LDL-cholesterol concentrations were found; c) serum HDL-cholesterol concentration increased slightly.Paraoxonase activity in the serum of rats maintained on a restricted diet, which induced approximately 30% and 50% of rat body weight and fat mass loss, respectively, was lower than in control animals.Conclusions. This study indicates that after VBG significant decreases in serum paraoxonase activity occur in obese subjects. It is likely that less food ingestion and possibly a different type of food consumed by the obese subjects after VBG (compared to type of food consumed before surgery) may contribute to decreases in serum PON activity.

Keywords

EN

paraoxonase (PON) activity; vertical banded gastroplasty (VBG); obesity; BMI

• Publisher: Index Copernicus International
• Journal: Polish Journal of Surgery
• Year: 2007
• Volume: 79
• Issue: 6
• Pages: 436-444

Dates

published

1 - 6 - 2007

online

27 - 11 - 2007

Contributors

author

Bartosz Goyke

• Department of Biochemistry, Medical University in Gdańsk

author

Elżbieta Goyke

• Department of Biochemistry, Medical University in Gdańsk

author

Tomasz Śledziński

• Department of Pharmaceutical Biochemistry, Medical University in Gdańsk

author

Krystian Adrych

• Department of Gastroenterology, Medical University in Gdańsk

author

Sylwia Raczyńska

• Department of General Surgery and Transplantology, Medical University in Gdańsk

author

Zbigniew Śledziński

• Department of General Surgery and Transplantology, Medical University in Gdańsk

author

Julian Świerczyński

• Department of Biochemistry, Medical University in Gdańsk

References

• Sklan EH, Lowenthal A, Korner M et al.: Acetylcholinesterase/paraoxonase genotype and expression predict anxiety scores in Health, Risk Factors, Exercise Training, and Genetics study. Proc Natl Acad Sci U S A 2004; 101: 5512-17.[Crossref]
• Li HL, Liu DP, Liang CC: Paraoxonase gene polymorphisms, oxidative stress, and diseases. J Mol Med 2003; 81: 766-79.[Crossref][PubMed]
• Getz GS, Reardon CA: Paraoxonase, a cardioprotective enzyme: continuing issues. Curr Opin Lipidol 2004; 15: 261-67.[PubMed][Crossref]
• Mackness MI, Harty D, Bhatnagar D et al.: Serum paraoxonase activity in familial hypercholesterolaemia and insulin-dependent diabetes mellitus. Atherosclerosis 1991; 86: 193-99.[Crossref][PubMed]
• Mackness MI, Arrol S, Durrington PN: Paraoxonase prevents accumulation of lipoperoxides in lowdensity lipoprotein. FEBS Lett 1991; 286: 152-54.
• Rozenberg O, Rosenblat M, Coleman R et al.: Paraoxonase (PON1) deficiency is associated with increased macrophage oxidative stress: studies in PON1-knockout mice. Free Radic Biol Med 2003; 34: 774-84.[PubMed][Crossref]
• Shih DM, Gu L, Hama S et al.: Genetic-dietary regulation of serum paraoxonase expression and its role in atherogenesis in a mouse model. J Clin Invest 1996; 97: 1630-39.[Crossref]
• Ayub A, Mackness MI, Arrol S et al.: Serum paraoxonase after myocardial intfarction. Arterioscler Thromb Vasc Biol 1999; 19: 330-35.[Crossref]
• Rozenberg O, Shih DM, Aviram M: Human serum paraoxonase 1 decreases macrophage cholesterol biosynthesis: biosynthesis: possible role for its phospholipase-A2-like activity and lysophosphatidylcholine formation. Arterioscler Thromb Vasc Biol 2003; 23: 461-67.[Crossref][PubMed]
• Jakubowski H: Calcium-dependent human serum homocysteine thiolactone hydrolase. A protective mechanism against protein N-homocysteinylation. J Biol Chem 2000; 275: 3957-62.
• McCully KS: Homocysteine and vascular disease. Nat Med 1996; 2: 386-89.[PubMed][Crossref]
• McCully KS, Wilson RB: Homocysteine theory of arteriosclerosis. Atherosclerosis 1975; 22: 215-27.[PubMed][Crossref]
• Jakubowski H: Homocysteine thiolactone: metabolic origin and protein homocysteinylation in humans. J Nutr 2000; 130: 377S-381S.
• Jakubowski H, Ambrosius WT, Pratt JH: Genetic determinants of homocysteine thiolactonase activity in humans: implications for atherosclerosis. FEBS Lett 2001; 491: 35-39.
• Fenster CP, Weinsier RL, Darley-Usmar VM et al.: Obesity, aerobic exercise, and vascular disease: the role of oxidant stress. Obes Res 2002; 10: 964-68.[Crossref]
• Manson JE, Colditz GA, Stampfer MJ et al.: A prospective study of obesity and risk of coronary heart disease in women. N Engl J Med 1990; 322: 882-89.[WoS]
• Ross R: Atherosclerosis - an inflammatory disease. N Engl J Med 1999; 340: 115-26.
• Williams IL, Wheatcroft SB, Shah AM et al.: Obesity, atherosclerosis and the vascular endothelium: mechanisms of reduced nitric oxide bioavailability in obese humans. Int J Obes Relat Metab Disord 2002; 26: 754-64.
• James RW, Brulhart-Meynet MC, Lehmann T et al.: Lipoprotein distribution and composition in obesity: their association with central adiposity. Int J Obes Relat Metab Disord 1997; 21: 1115-20.[PubMed][Crossref]
• Ferretti G, Bacchetti T, Moroni C et al.: Paraoxonase activity in high-density lipoproteins: a comparison between healthy and obese females. J Clin Endocrinol Metab 2005; 90: 1728-33.[Crossref][PubMed]
• Uzun H, Zengin K, Taskin M et al.: Changes in leptin, plasminogen activator factor and oxidative stress in morbidly obese patients following open and laparoscopic Swedish adjustable gastric banding. Obes Surg 2004; 14: 659-65.[Crossref]
• Sampson MJ, Braschi S, Willis G et al.: Paraoxonase-1 (PON-1) genotype and activity and in vivo oxidized plasma low-density lipoprotein in Type II diabetes. Clin Sci (Lond) 2005; 109: 189-97.
• Reddy ST, Wadleigh DJ, Grijalva V et al.: Human paraoxonase-3 is an HDL-associated enzyme with biological activity similar to paraoxonase-1 protein but is not regulated by oxidized lipids. Arterioscler Thromb Vasc Biol 2001; 21: 542-47.[Crossref]
• Ng CJ, Wadleigh DJ, Gangopadhyay A et al.: Paraoxonase-2 is a ubiquitously expressed protein with antioxidant properties and is capable of preventing cell-mediated oxidative modification of low density lipoprotein. J Biol Chem 2001; 276: 44444-49.
• Draganov DI, Stetson PL, Watson CE et al.: Rabbit serum paraoxonase 3 (PON3) is a high density lipoprotein-associated lactonase and protects low density lipoprotein against oxidation. J Biol Chem 2000; 275: 33435-42.
• Eckerson HW, Romson J, Wyte C et al.: The human serum paraoxonase polymorphism: identification of phenotypes by their response to salts. Am J Hum Genet 1983; 35: 214-27.[PubMed]
• Eckerson HW, Wyte CM, La Du BN: The human serum paraoxonase/arylesterase polymorphism. Am J Hum Genet 1983; 35: 1126-38.[PubMed]
• Zabrocka L, Raczynska S, Goyke E et al.: BMI is the main determinant of the circulating leptin in women after vertical banded gastroplasty. Obes Res 2004; 12: 505-12.[PubMed][Crossref]
• Ferre N, Camps J, Fernandez-Ballart J et al.: Regulation of serum paraoxonase activity by genetic, nutritional, and lifestyle factors in the general population. Clin Chem 2003; 49: 1491-97.[Crossref]
• Thomas-Moya E, Gianotti M, Llado I et al.: Effects of caloric restriction and gender on rat serum paraoxonase 1 activity. J Nutr Biochem 2006; 17: 197-203.[Crossref]
• Rantala M, Silaste ML, Tuominen A et al.: Dietary modifications and gene polymorphisms alter serum paraoxonase activity in healthy women. J Nutr 2002; 132: 3012-17.
• Kleemola P, Freese R, Jauhiainen M et al.: Dietary determinants of serum paraoxonase activity in healthy humans. Atherosclerosis 2002; 160: 425-32.
• Geloneze B, Tambascia MA, Pareja JC et al.: The insulin tolerance test in morbidly obese patients undergoing bariatric surgery. Obes Res 2001; 9: 763-69.[Crossref]
• Abbott CA, Mackness MI, Kumar S et al.: Serum paraoxonase activity, concentration, and phenotype distribution in diabetes mellitus and its relationship to serum lipids and lipoproteins. Arterioscler Thromb Vasc Biol 1995; 15: 1812-18.[Crossref]
• Kumon Y, Nakauchi Y, Kidawara K et al.: A longitudinal analysis of alteration in lecithin-cholesterol acyltransferase and paraoxonase activities following laparoscopic cholecystectomy relative to other parameters of HDL function and the acute phase response. Scand J Immunol 1998; 48: 419-24.[PubMed][Crossref]
• Kelso GJ, Stuart WD, Richter RJ et al.: Apolipoprotein J is associated with paraoxonase in human plasma. Biochemistry 1994; 33: 832-39.[PubMed][Crossref]
• Manson JE, Willett WC, Stampfer MJ et al.: Body weight and mortality among women. N Engl J Med 1995; 333: 677-85.
• Ginsberg HN, Zhang YL, Hernandez-Ono A: Metabolic syndrome: focus on dyslipidmia. Obesity (Silver Spring), 2006; 14 suppl 1: 20S-24S.[Crossref]
• Zimmet PZ, Alberti KG: Introduction: Globalization and the non-communicable disease epidemic. Obesity (Silver Spring), 2006; 14(1): 1-3.[Crossref]
• Lynch RJ, Eisenberg D, Bell RL: Metabolic consequences of bariatric surgery. J Clin Gastroenterol 2006; 40(8): 659-68.[Crossref][PubMed]
• Scott SK, Rabito FA, Price PD et al.: Comorbidity among the morbidly obese: a comparrative study of 2002 US hospital patient discharges. Obes Relat Dis 2006; 2(2): 105-11.[Crossref]

Identifiers

DOI

10.2478/v10035-007-0067-x